Hematology

Research highlights the importance of regular blood testing to impove earlier detection of multiple myeloma.

Study recommends similar clinical thresholds for diagnosing and managing giant cell arteritis for patients of different ethnicities.

The approval of fedratinib (Inrebic, Celgene) provides another treatment option for patients with myelofibrosis, a rare bone marrow disorder.

If approved, acalabrutinib (Calquence, AstraZeneca) will offer a chemotherapy-free treatment option for adults with chronic lymphocytic leukemia.

The number of first-degree relatives affected by blood cancer and age of diagnosis may contribute to the likelihood of a family member’s risk of being diagnosed with the same disease.

A recent study analyzed the 10-year absolute risks of thromboembolism and bleeding in patients with a history of hematologic cancer.

Selinexor (Xpovio, Karyopharm) received approval in combination with dexamethasone for heavily-pretreated patients with relapsed or refractory multiple myeloma.

Daratumumab (Darzalex, Janssen) is indicated for use in combination with lenalidomide and dexamethasone for patients with newly-diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Daratumumab (Darzalex, Janssen) is indicated for use in combination with lenalidomide and dexamethasone for patients with newly-diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Since the growth of specialty pharmacies, genetically acquired bleeding disorders such as von Willebrand disease (vWD) have been among the most common conditions addressed in these practice locations.

Slow walking speed associated with higher risk of poor outcomes for older patients with blood cancers.

Lenalidomide found to prevent the formation of blood vessels that feed tumors, yet carries significant adverse effects.

In a Specialty Pharmacy Times® Practice Pearls video series, expert panelists convened to discuss the challenges and best practices for dispensing multiple myeloma medications.

Treatment with tagraxofusp yielded high response rates in patients with blastic plasmacytoid dendritic cell neoplasm.

A certain type of DNA rearrangement that is rarely tested for may be a predictor of prognosis in multiple myeloma.

Since the growth of specialty pharmacies, genetically acquired bleeding disorders such as von Willebrand disease (VWD) have been among the most common conditions addressed at these practice locations.

In this clip from the Hematology/Oncology Pharmacy Association, Alison Duffy, PharmD, BCOP, from the University of Maryland Greenbaum Comprehensive Cancer Center, shares important considerations in treating Chronic Lymphocytic Leukemia in patients.

The daratumumab (Darzalex) combination therapy would be the first for use in the frontline setting for transplant-eligible patients with multiple myeloma.

Interim phase 3 trial results showed an increased risk of death for patients receiving venetoclax for multiple myeloma.

Celgene Corporation’s lenalidomide (Revlimid) is a targeted therapy that stops the growth of myeloma cells in the bone marrow.

The latest sBLA is based on a phase 3 study evaluating the daratumumab combination regimen for newly-diagnosed patients with multiple myeloma who are ineligible for transplantation.

Phase 3 trial evaluating isatuximab in combination with standard of care met the primary endpoint of prolonging progression-free survival.

Daratumumab was first approved in November 2015 as the first and only CD38-directed antibody for the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double refractory to both.

The new approval allows for daratumumab (Darzalex) to be administered as a split infusion over 2 consecutive days.

Researchers at University of Texas Health Science Center at San Antonio studied 28,000 childhood cancer survivors to determine similarities in long-term effects for various chemotherapies.

Two recent studies analyzed factors that impacted response to therapy in patients with multiple myeloma.

The FDA has approved tagraxofusp-erzs (Elzonris, Stemline Therapeutics) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients, aged 2 years and older.

A phase 2 study demonstrated promising response rates and overall survival in patients with acute myeloid leukemia who were treated with azacitidine plus nivolumab.

Leukemia is a type of cancer that affects blood cell formation and the lymphatic system. It can be classified by cell type, lymphoid or myeloid, and the rate of progression, acute or chronic.

The drug’s application was designated for fast track and priority review, as well as orphan product status.